The Biotech Rally Isn't Over Yet


Biotech has been on a tear recently, and Barclays' Paul Choi and Geoff Meacham write that investor will probably stay positive on the sector. They attribute the recent rally to the expectation that more deals may be in the pipeline following Gilead and Kite Pharma , the fact that political clamor over drug prices seems to have receded , and the potential that tax reform may happen.



from Biotech News